Exact Mass: 473.21752720000006
Exact Mass Matches: 473.21752720000006
Found 140 metabolites which its exact mass value is equals to given mass value 473.21752720000006
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
CD 1790
C25H27N7O3 (473.21752720000006)
CD 1790 is a metabolite of linagliptin. Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly. (Wikipedia)
Ala Pro Thr Trp
Ala Pro Trp Thr
Ala Gln Gln Gln
Ala Thr Pro Trp
Ala Thr Trp Pro
Ala Trp Pro Thr
Ala Trp Thr Pro
Asp Asp Lys Pro
C19H31N5O9 (473.21216760000004)
Asp Asp Pro Lys
C19H31N5O9 (473.21216760000004)
Asp Lys Asp Pro
C19H31N5O9 (473.21216760000004)
Asp Lys Pro Asp
C19H31N5O9 (473.21216760000004)
Asp Pro Asp Lys
C19H31N5O9 (473.21216760000004)
Asp Pro Lys Asp
C19H31N5O9 (473.21216760000004)
Asp Pro Arg Ser
Asp Pro Ser Arg
Asp Arg Pro Ser
Asp Arg Ser Pro
Asp Ser Pro Arg
Asp Ser Arg Pro
Glu Pro Gln Thr
C19H31N5O9 (473.21216760000004)
Glu Pro Thr Gln
C19H31N5O9 (473.21216760000004)
Glu Gln Pro Thr
C19H31N5O9 (473.21216760000004)
Glu Gln Thr Pro
C19H31N5O9 (473.21216760000004)
Glu Thr Pro Gln
C19H31N5O9 (473.21216760000004)
Glu Thr Gln Pro
C19H31N5O9 (473.21216760000004)
Phe Asn Pro Pro
Phe Pro Asn Pro
Phe Pro Pro Asn
Ile Asn Asn Asn
Lys Asp Asp Pro
C19H31N5O9 (473.21216760000004)
Lys Asp Pro Asp
C19H31N5O9 (473.21216760000004)
Lys Pro Asp Asp
C19H31N5O9 (473.21216760000004)
Leu Asn Asn Asn
Asn Phe Pro Pro
Asn Ile Asn Asn
Asn Leu Asn Asn
Asn Asn Ile Asn
Asn Asn Leu Asn
Asn Asn Asn Ile
Asn Asn Asn Leu
Asn Asn Gln Val
Asn Asn Val Gln
Asn Pro Phe Pro
Asn Pro Pro Phe
Asn Gln Asn Val
Asn Gln Val Asn
Asn Val Asn Gln
Asn Val Gln Asn
Pro Ala Thr Trp
Pro Ala Trp Thr
Pro Asp Asp Lys
C19H31N5O9 (473.21216760000004)
Pro Asp Lys Asp
C19H31N5O9 (473.21216760000004)
Pro Asp Arg Ser
Pro Asp Ser Arg
Pro Glu Gln Thr
C19H31N5O9 (473.21216760000004)
Pro Glu Thr Gln
C19H31N5O9 (473.21216760000004)
Pro Phe Asn Pro
Pro Phe Pro Asn
Pro Lys Asp Asp
C19H31N5O9 (473.21216760000004)
Pro Asn Phe Pro
Pro Asn Pro Phe
Pro Pro Phe Asn
Pro Pro Asn Phe
Pro Gln Glu Thr
C19H31N5O9 (473.21216760000004)
Pro Gln Thr Glu
C19H31N5O9 (473.21216760000004)
Pro Arg Asp Ser
Pro Arg Ser Asp
Pro Ser Asp Arg
Pro Ser Arg Asp
Pro Thr Ala Trp
Pro Thr Glu Gln
C19H31N5O9 (473.21216760000004)
Pro Thr Gln Glu
C19H31N5O9 (473.21216760000004)
Pro Thr Trp Ala
Pro Trp Ala Thr
Pro Trp Thr Ala
Gln Ala Gln Gln
Gln Glu Pro Thr
C19H31N5O9 (473.21216760000004)
Gln Glu Thr Pro
C19H31N5O9 (473.21216760000004)
Gln Asn Asn Val
Gln Asn Val Asn
Gln Pro Glu Thr
C19H31N5O9 (473.21216760000004)
Gln Pro Thr Glu
C19H31N5O9 (473.21216760000004)
Gln Gln Ala Gln
Gln Gln Gln Ala
Gln Thr Glu Pro
C19H31N5O9 (473.21216760000004)
Gln Thr Pro Glu
C19H31N5O9 (473.21216760000004)
Gln Val Asn Asn
Arg Asp Pro Ser
Arg Asp Ser Pro
Arg Pro Asp Ser
Arg Pro Ser Asp
Arg Ser Asp Pro
Arg Ser Pro Asp
Ser Asp Pro Arg
Ser Asp Arg Pro
Ser Pro Asp Arg
Ser Pro Arg Asp
Ser Arg Asp Pro
Ser Arg Pro Asp
Thr Ala Pro Trp
Thr Ala Trp Pro
Thr Glu Pro Gln
C19H31N5O9 (473.21216760000004)
Thr Glu Gln Pro
C19H31N5O9 (473.21216760000004)
Thr Pro Ala Trp
Thr Pro Glu Gln
C19H31N5O9 (473.21216760000004)
Thr Pro Gln Glu
C19H31N5O9 (473.21216760000004)
Thr Pro Trp Ala
Thr Gln Glu Pro
C19H31N5O9 (473.21216760000004)
Thr Gln Pro Glu
C19H31N5O9 (473.21216760000004)
Thr Trp Ala Pro
Thr Trp Pro Ala
Val Asn Asn Gln
Val Asn Gln Asn
Val Gln Asn Asn
Trp Ala Pro Thr
Trp Ala Thr Pro
Trp Pro Ala Thr
Trp Pro Thr Ala
Trp Thr Ala Pro
Trp Thr Pro Ala
NBD-FTY720 phenoxy
4-[5-(2-chlorophenyl)-4-[4-(dimethylamino)phenyl]-oxazol-2-yl]-N,N-dipropyl-aniline
Simenepag isopropyl
C26H35NO5S (473.2235820000001)
C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent
2-imino-10-methyl-N-[2-(4-morpholinyl)ethyl]-5-oxo-1-(3-pyridinylmethyl)-3-dipyrido[3,4-c:1,2-f]pyrimidinecarboxamide
C25H27N7O3 (473.21752720000006)
4-amino-N5-(4-butoxyphenyl)-N5-[2-(cyclohexylamino)-2-oxoethyl]isothiazole-3,5-dicarboxamide
C23H31N5O4S (473.20966460000005)
4-[2-[(1-acetyl-4-oxo-6-spiro[3,4-dihydro-2H-1-benzopyran-2,4-piperidine]yl)oxy]-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester
[(1S)-7-methoxy-1,9-dimethyl-2-[(1-methyl-4-imidazolyl)sulfonyl]-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C23H31N5O4S (473.20966460000005)
[(1R)-7-methoxy-1,9-dimethyl-2-[(1-methyl-4-imidazolyl)sulfonyl]-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C23H31N5O4S (473.20966460000005)
Usmarapride
Usmarapride (SUVN-D4010) is a potent, selective, orally active and brain penetrant 5-HT4 receptor partial agonist (EC50=44 nM). Usmarapride (SUVN-D4010) can be used for the research of cognitive deficits associated with Alzheimer's disease[1].